MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

The latest financial statement is for the quarter ending 2025-09-30.

Cash Flow Overview

Free Cash flow
-$2,594K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-3,170 469
Amortization of debt discount
190 381
Depreciation and amortization
364 773
Amortization of right-of-use asset
37 72
Write-off of patent cost
176 -
Write-off of inventory
0 253
Bad debt expense
8 9
Stock-based compensation
488 1,391
Foreign currency transaction gains
-64 9,192
Accounts receivable
-303 -257
Inventories
322 925
Prepaid expenses and other current assets
908 -1,897
Accounts payable and accrued expenses
193 -360
Net cash used in operating activities
-2,577 -4,975
Purchases of property and equipment
17 39
Payments for patent costs
-72 140
Net cash used in investing activities
55 -179
Proceeds from exercise of common stock warrants
0 1,439
Proceeds from rights offering, net of fees incurred
0 5,392
Net cash provided by financing activities
0 6,831
Effect of exchange rates on cash
-146 285
Net change in cash, cash equivalents, and restricted cash
-2,668 1,962
Cash and cash equivalents at beginning of period
9,764 -
Cash and cash equivalents at end of period
9,058 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Cytosorbents Corp (CTSO)

Cytosorbents Corp (CTSO)